Home › Calculator › ERAS Dividend Calculator 2026
ERAS Dividend DRIP Calculator 2026
10.89% YieldHealthcareErasca, Inc. · NASDAQ
Price: $18.36 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ERAS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ERAS snowball 📈
$10,000 in ERAS → $28.1K in 10 years · $230.21/month
About Erasca, Inc. (ERAS) — Dividend Analysis 2026
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Compare ERAS with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ERAS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ERAS position with:
🌍 ERAS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ERAS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 10.89% | 8.09% | $1,089 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 9.26% | 6.46% | $926 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 8.71% | 5.91% | $871 / yr |
| 🇬🇧 UK ISA | 0% | 10.89% | 8.09% | $1,089 / yr |
| 🇬🇧 UK Taxable | 8.75% | 9.94% | 7.14% | $994 / yr |
| 🇨🇦 TFSA | 0% | 10.89% | 8.09% | $1,089 / yr |
| 🇨🇦 CA Taxable | 25% | 8.17% | 5.37% | $817 / yr |
| 🇦🇺 Super (pension) | 15% | 9.26% | 6.46% | $926 / yr |
| 🇦🇺 AU Taxable | 30% | 7.62% | 4.82% | $762 / yr |
| 🇩🇪 DE Taxable | 26.375% | 8.02% | 5.22% | $802 / yr |
| 🇫🇷 FR Taxable | 30% | 7.62% | 4.82% | $762 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ERAS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ERAS Dividend Payment Schedule
ERAS pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ERAS vs Healthcare Benchmarks
How ERAS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ERAS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ERAS Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| A-Award | 2026-06-26 | 29,888 | $16.01 | $478.5K | ||
| M-Exempt | 2026-04-01 | 80,000 | $1.70 | $136.0K | ||
| M-Exempt | 2026-04-01 | 80,000 | $1.70 | $136.0K | ||
| Sale | 2026-04-01 | 80,000 | $16.40 | $1.31M | ||
| M-Exempt | 2025-03-04 | 20,000 | $1.70 | $34.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ERAS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Erasca, Inc. (ERAS) is currently trading at $18.36, 20% below its 52-week high. The current dividend yield is 10.89% based on an annual payout of $2.00 per share.
ERAS (Erasca, Inc.) — 10.89% Dividend Yield Analysis
Erasca, Inc. (ERAS) is a healthcare stock currently trading at $18.36 with a dividend yield of 10.89%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (10.89%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ERAS News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.